Literature DB >> 33530590

Reproducibility of Baseline Tumour Metabolic Volume Measurements in Diffuse Large B-Cell LymphomA: Is There a Superior Method?

Florian Eude1,2, Mathieu Nessim Toledano1,2, Pierre Vera1,2, Hervé Tilly3,4, Sorina-Dana Mihailescu5, Stéphanie Becker1,2.   

Abstract

The metabolic tumour volume (MTV) is an independent prognostic indicator in diffuse large B-cell lymphoma (DLBCL). However, its measurement is not standardised and is subject to wide variations depending on the method used. This study aimed to compare the reproducibility of MTV measurement as well as the thresholds obtained for each method and their prognostic values. The baseline MTV was measured in 239 consecutive patients treated at Henri Becquerel Centre by two blinded evaluators. Eight methods were compared: 3 absolute (SUV (standardised uptake value) ≥ 2.5; SUV≥ liver SUVmax; SUV≥ PERCIST SUV), 1 percentage SUV threshold method (SUV ≥ 41% SUVmax) and 4 adaptive methods (Daisne, Nestle, Fitting, Black). The intraclass correlation coefficients were excellent, from 0.91 to 0.96, for the absolute SUV methods, Black and Nestle methods, and good for 41% SUVmax, Fitting and Daisne methods (0.82 to 0.88), with a significantly lower variability with absolute methods compared to 41% SUVmax (p < 0.04). Thresholds were found to be specific to each segmentation method and ranged from 295 to 552 cm3. There was a strong correlation between the MTV and patient prognosis regardless of the segmentation method used (p = 0.001 for PFS and OS). The largest inter-observer cut-off variability was observed in the 41% SUVmax method, which resulted in more inter-observer disagreements in the classification of patients between high and low MTV groups. MTV measurements based on absolute SUV criteria were found to be significantly more reproducible than those based on 41% SUVmax criteria. The threshold was specific for each of eight segmentation methods, but all predicted prognosis.

Entities:  

Keywords:  large B-Cell lymphoma; metabolic tumour volume; positron-emission tomography; segmentation

Year:  2021        PMID: 33530590     DOI: 10.3390/metabo11020072

Source DB:  PubMed          Journal:  Metabolites        ISSN: 2218-1989


  5 in total

1.  Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters.

Authors:  Zsombor Ritter; László Papp; Katalin Zámbó; Zoltán Tóth; Dániel Dezső; Dániel Sándor Veres; Domokos Máthé; Ferenc Budán; Éva Karádi; Anett Balikó; László Pajor; Árpád Szomor; Erzsébet Schmidt; Hussain Alizadeh
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

2.  Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.

Authors:  Sofia Genta; Guido Ghilardi; Luciano Cascione; Darius Juskevicius; Alexandar Tzankov; Sämi Schär; Lisa Milan; Maria Cristina Pirosa; Fabiana Esposito; Teresa Ruberto; Luca Giovanella; Stefanie Hayoz; Christoph Mamot; Stefan Dirnhofer; Emanuele Zucca; Luca Ceriani
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

3.  Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin's lymphoma.

Authors:  Pierre Pinochet; Edgar Texte; Aspasia Stamatoullas-Bastard; Pierre Vera; Sorina-Dana Mihailescu; Stéphanie Becker
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

4.  Prognostic Value of 18F-FDG PET/CT Volume-Based Metabolic Parameters in Patients with Node-Negative Stage II Esophageal Squamous Cell Carcinoma.

Authors:  Daniel Hueng-Yuan Shen; Hung-Pin Chan; Fu-Ren Tsai; Chin Hu; Allan Yi-Nan Chen; Hung-Yen Chan; Che-Hsin Lee; Kuo-Pin Chuang; Ming-Hui Yang; Yu-Chang Tyan
Journal:  Metabolites       Date:  2021-12-22

Review 5.  Metabolic Volume Measurements in Multiple Myeloma.

Authors:  Maria Emilia Seren Takahashi; Irene Lorand-Metze; Carmino Antonio de Souza; Claudio Tinoco Mesquita; Fernando Amorim Fernandes; José Barreto Campello Carvalheira; Celso Dario Ramos
Journal:  Metabolites       Date:  2021-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.